Xu, Hong-Rong
Zhang, Jin-Wen
Chen, Wei-li
Ning, Zhi-Qiang
Li, Xue-Ning
Funding for this research was provided by:
the Shenzhen Science and Technology Innovation Committee (No. CXZZ20151013171242907)
National Foundation for Science and Technology Development (No. 2002AA2Z3146)
National Science and Technology Significant Project in the category “New Drug Initiative” (2008ZX09101-002)
Article History
First Online: 29 April 2019
Compliance with Ethical Standards
:
: Jin-Wen Zhang and Zhi-Qiang Ning are employees of Shenzhen Chipscreen Biosciences Co., Ltd. Hong-Rong Xu, Wei-Li Chen and Xue-Ning Li are employees of ZhongShan Hospital, Fudan University, and declare that they have no conflicts of interest in this study.
: The study was supported by the following project Grants: (1) “Research on the pharmacokinetics of chiglitazar tablet, a new drug in category 1.1 for diabetes” (No. CXZZ20151013171242907) from the Shenzhen Science and Technology Innovation Committee; (2) a National Science and Technology “863” Project (No. 2002AA2Z3146); and (3) a National Science and Technology Significant Project in the category “New Drug Initiative” (2008ZX09101-002).
: The study protocol was approved by the independent ethics committee and the institutional review board of the ZhongShan Hospital, Fudan University. The study was performed in accordance with the Declaration of Helsinki, the Good Clinical Practice Guidelines and local laws.
: Written informed consent was obtained from all individual participants prior to their enrolment.